PHAXIAM Therapeutics S.A. is an innovative biopharmaceutical company headquartered in Lyon, France, dedicated to combating resistant bacterial infections through the development of advanced therapeutic solutions. With a robust pipeline of proprietary candidates progressing through various stages of clinical development, PHAXIAM is addressing the critical global challenge of antibiotic resistance. The company's strategic focus on pioneering therapies not only positions it as a potential leader in the biopharmaceutical industry but also reflects its commitment to improving patient outcomes and enhancing public health on a global scale. Show more

Location: 60 AVENUE ROCKEFELLER, LYON, FRANCE, 69008, USA | Website: https://www.phaxiam.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

28.9M

52 Wk Range

$0.00 - $0.00

Previous Close

$3.10

Open

$3.10

Volume

N/A

Day Range

$3.10 - $3.10

Enterprise Value

0.00

Cash

10.47M

Avg Qtr Burn

-12.55M

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

12/31/22

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PHAXIAM phages Details Staph aureus , Prosthetic joint infection	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PHAXIAM phages Details Endocarditis infections, Staph aureus	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Pancreatic cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Leukemia, Acute lymphoblastic leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eryaspase (GRASPA) (asparaginase) Details Breast cancer, Triple-negative breast cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.